Unique T-cell subpopulation changes following combination SBPT and Nivolumab in platinum refractory HNSCC: Biomarker correlates from ROR1771
Daniel K. Ebner(National Institutes for Quantum Science and Technology), Jane Evans(Intermountain Healthcare), Katharine A. Price(WinnMed), Samir H. Patel(WinnMed), H. Dong(Mayo Clinic), Y. Garces(Mayo Clinic), Mauricio E. Gamez(Mayo Clinic), M.A. Neben-Wittich(Mayo Clinic), Ashish V. Chintakuntlawar(Mayo Clinic Hospital), Scott C. Lester(Mayo Clinic in Arizona), Robert L. Foote(Mayo Clinic), JEFF EVANS(Intermountain Healthcare), Dengyan Ma(Mayo Clinic), Bodil Christensen(Intermountain Healthcare), L.A. McGee, D. Routman(Mayo Clinic), J. Breinholt(Novo Nordisk (Denmark)), S. Park(Mayo Clinic)
Cited by 0
Related Papers
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2017|378
Head and Neck Cancers, Version 1.2015
|Journal of the National Comprehensive Cancer Network|2015|269